Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Inpatient and Ambulatory, Phase 2, Double Blind, Randomized, Placebo-controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia

NCT00861796 is registered in ClinicalTrials.gov with Cyrenaic Pharmaceuticals as lead sponsor.

NCT NCT00861796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00861796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Inpatient and Ambulatory, Phase 2, Double Blind, Randomized, Placebo-controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia
Lead sponsor
Cyrenaic Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
June 30, 2010
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia